Testing for expression of ER, PR, and HER2/neu is now universally recommended in all invasive breast carcinoma patients that serve not only as prognostic biomarkers but also as predictive markers for determining adjuvant therapy (3, 19, 20). The gene discussed is ERBB2; the disease is invasive breast carcinoma.